Henry Schein, Inc.

Henry Schein, Inc. is an American health care solutions company that serves as the world's largest distributor of health care products and services to office-based dental and medical practitioners, generating $13.18 billion in revenue in fiscal 2025. The company operates through three segments: Global Distribution and Value-Added Services, which accounts for roughly 85% of sales through the distribution of dental and medical consumables, equipment, and related services; Global Specialty Products, which manufactures and markets dental implants, biomaterials, endodontics, orthodontics, and orthopedic products; and Global Technology, which develops and distributes practice management software and e-services to health care providers.

This is a story about a distribution franchise with durable competitive advantages — infrastructure density, customer relationships built over 94 years, and a widening moat in integrated technology — that is simultaneously digesting a CEO transition, executing a restructuring, and trying to prove that its specialty and technology segments can shift the earnings mix toward sustainably higher margins. The company emerged from a 2023 cyber incident with renewed commercial momentum, and its new CEO arrives with a mandate to sharpen operational execution. The file turns on a single question: whether Henry Schein can convert its dominant distribution position into a compounding earnings story, or whether the distribution business's structural margin ceiling keeps the company anchored as a GDP-plus compounder with occasional bursts of value creation.

Henry Schein is not a complicated business to describe, but it is a difficult one to evaluate. It sells a vast catalog of largely unglamorous products — gloves, anesthetics, dental chairs, practice management software — to customers who need them every day. Its competitive position looks formidable: the company serves over one million customers in 34 countries, ships roughly 150,000 cartons daily from 38 distribution centers, and is the primary distributor for most national dental service organizations in the United States. Yet the stock has been a serial disappointer for much of the past five years, as GAAP earnings per share fell from $4.45 in fiscal 2021 to $3.27 in fiscal 2025, weighed down by acquisition integration costs, restructuring charges, and the cyber incident. The market has been patient — paying roughly 15x forward non-GAAP earnings at recent prices — but the thesis requires conviction that the earnings trajectory is finally inflecting upward.